Covalon Technologies (COV) Stock Price, News & Analysis

Company Overview

Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally. The company's platform technologies comprise collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity. It also offers medical coating platform, a process that utilizes photo-polymerization to create active grafting sites where new polymer chains are initiated and propagated from the surface of an existing medical device. In addition, the company provides wound care dressings; surgical and peri-operative; and infection management products. It offers its products under the Covalon brand name through third-party distribution networks and company's direct sales force. The company serves hospitals, wound care centers, burn centers, extended/alternate care and acute care facilities, home health care agencies, and physicians' offices. Covalon Technologies Ltd. is headquartered in Mississauga, Canada.

Key Stats

• Today's Range: C$3.15 to C$3.30
• 50-Day Range: C$2.44 to C$3.40
• 52-Week Range: C$0.96 to C$3.46
• Volume: 40,686 shs
• Average Volume: 19,374 shs
• Market Capitalization: C$87.13 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

COV Stock Analysis - Frequently Asked Questions

How have COV shares performed this year?

Covalon Technologies' stock was trading at C$1.06 at the beginning of the year. Since then, COV stock has increased by 200.0% and is now trading at C$3.18.
View the best growth stocks for 2024 here.

How were Covalon Technologies' earnings last quarter?

Covalon Technologies Ltd. (CVE:COV) released its earnings results on Wednesday, August, 21st. The company reported $0.06 EPS for the quarter. The firm earned $9.22 million during the quarter. Covalon Technologies had a negative net margin of 2.82% and a negative trailing twelve-month return on equity of 3.85%.

How do I buy shares of Covalon Technologies?

Shares of COV stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What other stocks do shareholders of Covalon Technologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Covalon Technologies investors own include NIO (NIO), Reliq Health Technologies (RHT), Facedrive (FDVRF), Meta Platforms (META), NVIDIA (NVDA), Ackroo (AKR) and BeWhere (BEW).

Company Calendar

• Last Earnings: 8/21/2024
• Today: 10/17/2024
• Next Earnings (Estimated): 1/24/2025

Industry, Sector and Symbol

• Stock Exchange: CVE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: CVE:COV
• CUSIP: N/A
• CIK: N/A
• Web: www.covalon.com
• Phone: +1-905-5688400
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): C($0.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 10.60
• P/E Growth: N/A
• Net Income: C$-2,770,000.00
• Net Margins: -2.82%
• Pretax Margin: N/A
• Return on Equity: -3.85%
• Return on Assets: -3.25%

Debt

• Debt-to-Equity Ratio: 4.98
• Current Ratio: 5.24
• Quick Ratio: 6.45

Sales & Book Value

• Annual Sales: C$29.20 million
• Price / Sales: 2.98
• Cash Flow: C$0.74 per share
• Price / Cash Flow: 4.28
• Book Value: C$0.88 per share
• Price / Book: 3.61

Miscellaneous

• Outstanding Shares: 27,400,000
• Free Float: N/A
• Market Cap: C$87.13 million
• Optionable: Not Optionable
• Beta: 0.64